Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that REAL-Time Continuous Glucose Monitoring (RT-CGM) will be more effective if introduced in children and adolescents with established diabetes at the same time as they are starting pump therapy. This randomized controlled trial will compare the effectiveness of simultaneous vs delayed introduction of RT-CGM in children and adolescents with type 1 diabetes who are starting insulin pump therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

NCT00357890

Diabetes Mellitus, Insulin-Dependent

COMPLETED NA

Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT01586065

Type 1 Diabetes

COMPLETED NA

Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study)

NCT02064647

Diabetes Mellitus, Type 1

COMPLETED NA

Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D

NCT04335513

Type 1 Diabetes Prediabetic State Dysglycemia +1 more

UNKNOWN NA

Assessing the Impact of Control-IQ Technology

NCT04838561

Type 1 Diabetes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

REAL-Time Continuous Glucose Monitoring (RT-CGM) improves diabetes control in adults with type 1 diabetes. However, studies of RT-CGM in children and adolescents have been mostly negative. The lack of effectiveness in the pediatric population appears directly related to adherence to RT-CGM, i.e., the willingness of children and teens to wear and use this technology. Most previous RT-CGM studies have focused on experienced pump users or children with new-onset diabetes. At the time of pump initiation, children and adolescents who have been living with diabetes (and their parents) are highly motivated to make changes in their diabetes management and to take on additional responsibilities to improve their diabetes control and lifestyle, the two primary reasons for initiating pump therapy in the pediatric population. The investigators hypothesize that readiness for making changes in diabetes management will be greater at the time of pump initiation than at six months after the pump start. Further, the investigators hypothesize that readiness for change at the time of RT-CGM initiation will predict future adherence to RT-CGM and its effectiveness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Simultaneous or Delayed initiation of continuous glucose monitoring

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Simultaneous RT-CGM and Pump Initiation

The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.

Group Type EXPERIMENTAL

Simultaneous RT-CGM and Pump Initiation

Intervention Type DEVICE

Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.

Delayed RT-CGM Initiation

The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.

Group Type ACTIVE_COMPARATOR

Delayed Initiation of RT-CGM

Intervention Type DEVICE

Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simultaneous RT-CGM and Pump Initiation

Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.

Intervention Type DEVICE

Delayed Initiation of RT-CGM

Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sensor-Augmented Pump Therapy at Pump Initiation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females age 5-18 years old.
* Established T1D diagnosis for a minimum of one year.
* Naïve to CSII therapy and ready to start CSII with the Veo pump (Medtronic) .
* Willing to use RT-CGM and to be randomly assigned to either simultaneous or delayed RT-CGM initiation.
* Regular diabetes follow up at one of the 5 participating sites.
* Internet access at home (to upload RT-CGM data).
* Parent(s) or legally acceptable representative able to speak and read English or French.
* Ability of the subject and parent(s) or legally acceptable representative to participate in all aspects of this clinical trial.
* Written informed consent must be obtained and documented, with assent of the child if \<14 years of age.

Exclusion Criteria

* Conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study.
* Has received oral and/or intravenous steroid therapy (for any indication, at any dose and/or for any duration) on more than 2 separate occasions in the past 12 months. Use of inhaled and/or topical steroid therapy in the last 12 months does not exclude the subject.
* Prior use of RT-CGM for more than 50% of the time over the past 6 months.
* Prior enrollment in the current study.
* Current enrollment in another intervention trial.

Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No